Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tego Science's EBITDA for the
three
months ended in Mar. 2026 was ₩-1,394 Mil. Tego Science's Revenue for the
three
months ended in Mar. 2026 was ₩1,198 Mil. Therefore, Tego Science's EBITDA margin for the quarter that ended in Mar. 2026 was -116.33%.
Tego Science (XKRX:191420) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tego Science EBITDA Margin % Related Terms
Tego Science EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tego Science's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tego Science's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tego Science EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tego Science's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tego Science's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tego Science (XKRX:191420) has a EBITDA Margin % of -116.33% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tego Science and its competitors. According to the industry distribution chart, Tego Science ranks #884 out of 958 companies in the Drug Manufacturers industry, placing it in the top 92.3%.
Is Tego Science's EBITDA Margin % too high?
Tego Science's current EBITDA Margin % is -116.33%. Based on the distribution chart, Tego Science ranks #884 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tego Science has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tego Science's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tego Science ranks #884 out of 958 companies for EBITDA Margin %. This places Tego Science in the lower half of its industry. The industry median EBITDA Margin % is 12.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tego Science and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tego Science's current EBITDA Margin % is -116.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tego Science stock overvalued right now?
Based on GuruFocus' analysis, Tego Science (XKRX:191420) is currently considered Possible Value Trap. The stock's GF Value™ is ₩13,243.11, compared to a current price of ₩6,650.00 — trading 49.8% below its estimated fair value. The current EBITDA Margin % is -116.33%. Tego Science's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tego Science (XKRX:191420), the current EBITDA Margin % is -116.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tego Science (XKRX:191420) Overvalued in 2026?
Based on GuruFocus' analysis, Tego Science stock appears to be undervalued.
The current stock price of ₩6,650.00 is trading 49.8% below its estimated GF Value™ of ₩13,243.11.
GuruFocus considers Tego Science to be Possible Value Trap.
Key valuation signals for XKRX:191420:
EBITDA Margin %: -116.33%
GF Value™: ₩13,243.11 vs. price of ₩6,650.00 (49.8% below fair value)
No single metric tells the full story. See the XKRX:191420 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tego Science Inc is a biotech company that researches and develops regenerative medicine. It is engaged in the production of epidermis and cornea wound healing solution. Its products include Holoderm, SkinBank, Kaloderm, and Neoderm. It also provides testing services.
56GF Score
Get the complete analysis for XKRX:191420
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:191420 has been successfully added to your 
